{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:39:02Z","timestamp":1787503142832,"version":"build-2736575974"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100019353","name":"Belgian Health Care Knowledge Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007660","name":"Universiteit Antwerpen","doi-asserted-by":"publisher","award":["VAX-ID \/ VAXINAID-C2P"],"award-info":[{"award-number":["VAX-ID \/ VAXINAID-C2P"]}],"id":[{"id":"10.13039\/501100007660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007660","name":"Universiteit Antwerpen","doi-asserted-by":"publisher","award":["VAX-ID \/ VAXINAID-C2P"],"award-info":[{"award-number":["VAX-ID \/ VAXINAID-C2P"]}],"id":[{"id":"10.13039\/501100007660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007660","name":"Universiteit Antwerpen","doi-asserted-by":"publisher","award":["VAX-ID \/ VAXINAID-C2P"],"award-info":[{"award-number":["VAX-ID \/ VAXINAID-C2P"]}],"id":[{"id":"10.13039\/501100007660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007660","name":"Universiteit Antwerpen","doi-asserted-by":"publisher","award":["VAX-ID \/ VAXINAID-C2P"],"award-info":[{"award-number":["VAX-ID \/ VAXINAID-C2P"]}],"id":[{"id":"10.13039\/501100007660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007660","name":"Universiteit Antwerpen","doi-asserted-by":"publisher","award":["VAX-ID \/ VAXINAID-C2P"],"award-info":[{"award-number":["VAX-ID \/ VAXINAID-C2P"]}],"id":[{"id":"10.13039\/501100007660","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01372-5","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:25:22Z","timestamp":1768832722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of maternal vaccine and\/or monoclonal antibody strategies against respiratory syncytial virus in Belgian infants"],"prefix":"10.1038","volume":"11","author":[{"given":"Xiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lander","family":"Willem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Roberfroid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke","family":"Bilcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Castanares Zapatero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"De Meester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuxin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Thiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Beutels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"1372_CR1","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","volume":"399","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 399, 2047\u20132064 (2022).","journal-title":"Lancet"},{"key":"1372_CR2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-2600(22)00414-3","volume":"11","author":"JG Wildenbeest","year":"2023","unstructured":"Wildenbeest, J. G. et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir. Med. 11, 341\u2013353 (2023).","journal-title":"Lancet Respir. Med."},{"key":"1372_CR3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/INF.0000000000004038","volume":"42","author":"N Bouckaert","year":"2023","unstructured":"Bouckaert, N., Lefevre, M., Van den Heede, K. & Van de Voorde, C. RSV burden and its impact on pediatric inpatient bed occupancy in Belgium: an analysis of National hospital claims data. Pediatr. Infect. Dis. J. 42, 857\u2013861 (2023).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"1372_CR4","doi-asserted-by":"crossref","first-page":"S599","DOI":"10.1093\/infdis\/jiaa360","volume":"222","author":"RM Reeves","year":"2020","unstructured":"Reeves, R. M. et al. Respiratory syncytial virus-associated hospital admissions in children younger than 5 years in 7 European countries using routinely collected datasets. J. Infect. Dis. 222, S599\u2013S605 (2020).","journal-title":"J. Infect. Dis."},{"key":"1372_CR5","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127065","volume":"55","author":"A Tilmanne","year":"2025","unstructured":"Tilmanne, A. et al. Evaluation of the costs of care for pediatric patients hospitalized for RSV: a retrospective cohort study in Belgium. Vaccine 55, 127065 (2025).","journal-title":"Vaccine"},{"key":"1372_CR6","doi-asserted-by":"publisher","unstructured":"Mao, Z. et al. Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: a multi-country prospective cohort study in Europe. Vaccine. https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.024 (2023).","DOI":"10.1016\/j.vaccine.2023.03.024"},{"key":"1372_CR7","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1093\/infdis\/jiac059","volume":"226","author":"RM Reeves","year":"2022","unstructured":"Reeves, R. M. et al. A systematic review of European clinical practice guidelines for respiratory syncytial virus prophylaxis. J. Infect. Dis. 226, S110\u2013S116 (2022).","journal-title":"J. Infect. Dis."},{"key":"1372_CR8","unstructured":"European Medicines Agency. Beyfortus : EPAR\u2014Product Information, <https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beyfortus> (2022)."},{"key":"1372_CR9","unstructured":"European Medicines Agency. Abrysvo : EPAR\u2014Product Information, <https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abrysvo> (2023)."},{"key":"1372_CR10","unstructured":"Superior Health Council. Preventive strategies against RSV disease in children, <https:\/\/www.health.belgium.be\/sites\/default\/files\/uploads\/fields\/fpshealth_theme_file\/20231222_shc-9760_advice_rsv_children_vweb.pdf> (2023)."},{"key":"1372_CR11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/AOG.0000000000005816","volume":"145","author":"EAF Simoes","year":"2025","unstructured":"Simoes, E. A. F. et al. Efficacy, safety, and immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal respiratory syncytial virus prefusion f protein vaccine trial. Obstet. Gynecol. 145, 157\u2013167 (2025).","journal-title":"Obstet. Gynecol."},{"key":"1372_CR12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S2352-4642(25)00102-6","volume":"9","author":"APS Munro","year":"2025","unstructured":"Munro, A. P. S. et al. 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial. Lancet Child Adolesc. Health 9, 404\u2013412 (2025).","journal-title":"Lancet Child Adolesc. Health"},{"key":"1372_CR13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMc2506107","volume":"393","author":"HJ Zar","year":"2025","unstructured":"Zar, H. J. et al. Clesrovimab in infants and children at increased risk for severe RSV disease. N. Engl. J. Med. 393, 1343\u20131345 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1372_CR14","unstructured":"Rijksinstituut voor ziekte\u2013en invaliditeitsverzekering (RIZIV\/INANI). Interpretatieregel voor vergoedingsvoorwaarden Beyfortus\u00ae (nirsevimab) na logistieke moeilijkheden, <https:\/\/www.riziv.fgov.be\/nl\/thema-s\/verzorging-kosten-en-terugbetaling\/wat-het-ziekenfonds-terugbetaalt\/geneesmiddelen\/interpretatieregel-voor-vergoedingsvoorwaarden-beyfortus-r-nirsevimab-na-logistieke-moeilijkheden> (2024)."},{"key":"1372_CR15","unstructured":"Belgisch Centrum voor Farmacotherapeutische Informatie. Beyfortus: list price, <https:\/\/www.bcfi.be\/nl\/chapters\/12?frag=8905127&view=pvt&vmp_group=48520> (2024)."},{"key":"1372_CR16","unstructured":"Belgisch Centrum voor Farmacotherapeutische Informatie. Abrysvo: list price, <https:\/\/www.bcfi.be\/nl\/chapters\/13?frag=mps-8904013> (2025)."},{"key":"1372_CR17","unstructured":"Li, X. et al. Cost-effectiveness of new preventive options against RSV infections in Belgian infants. (Belgian Health Care Knowledge Centre (KCE), Brussels, 2025)."},{"key":"1372_CR18","doi-asserted-by":"crossref","first-page":"e250380","DOI":"10.1001\/jamanetworkopen.2025.0380","volume":"8","author":"H Xu","year":"2025","unstructured":"Xu, H. et al. Estimated effectiveness of nirsevimab against respiratory syncytial virus. JAMA Netw. Open 8, e250380 (2025).","journal-title":"JAMA Netw. Open"},{"key":"1372_CR19","unstructured":"Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV). Vergoedbare Geneesmiddelen en Radio-Farmaceutische Producten, <https:\/\/webappsa.riziv-inami.fgov.be\/ssp\/ProductSearch> (2025)."},{"key":"1372_CR20","unstructured":"RIZIV-INAMI. Terugbetaling van Farmaceutische Specialiteiten uit Hoofdstuk IV en VIII: a priori controle, <https:\/\/www.riziv.fgov.be\/nl\/thema-s\/verzorging-kosten-en-terugbetaling\/wat-het-ziekenfonds-terugbetaalt\/geneesmiddelen\/geneesmiddel-terugbetalen\/vergoedbare-farmaceutische-specialiteiten\/lijst-van-farmaceutische-specialiteiten-de-hoofdstukken\/terugbetaling-van-farmaceutische-specialiteiten-uit-hoofdstuk-iv-en-viii-a-priori-controle>."},{"key":"1372_CR21","volume":"29","author":"X Li","year":"2024","unstructured":"Li, X., Bilcke, J. & Beutels, P. Pricey or priceless: cost-effectiveness of respiratory syncytial virus (RSV) prevention in infants. Lancet Reg. Health Am. 29, 100657 (2024).","journal-title":"Lancet Reg. Health Am."},{"key":"1372_CR22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2023.100392","volume":"15","author":"H Salo","year":"2023","unstructured":"Salo, H. et al. Prices of paediatric vaccines in European vaccination programmes. Vaccin. X 15, 100392 (2023).","journal-title":"Vaccin. X"},{"key":"1372_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00478-0","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(22)00478-0 (2022).","journal-title":"Lancet"},{"key":"1372_CR24","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0140-6736(23)00811-5","volume":"401","author":"C Rosas-Salazar","year":"2023","unstructured":"Rosas-Salazar, C. et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study. Lancet 401, 1669\u20131680 (2023).","journal-title":"Lancet"},{"key":"1372_CR25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S2213-2600(18)30055-9","volume":"6","author":"NM Scheltema","year":"2018","unstructured":"Scheltema, N. M. et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respir. Med. 6, 257\u2013264 (2018).","journal-title":"Lancet Respir. Med."},{"key":"1372_CR26","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S2213-2600(24)00246-7","volume":"12","author":"HJ Zar","year":"2024","unstructured":"Zar, H. J. et al. Early-life respiratory syncytial virus disease and long-term respiratory health. Lancet Respir. Med. 12, 810\u2013821 (2024).","journal-title":"Lancet Respir. Med."},{"key":"1372_CR27","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/infdis\/jiac064","volume":"226","author":"X Li","year":"2022","unstructured":"Li, X. et al. Cost-effectiveness of respiratory syncytial virus disease prevention strategies: maternal vaccine versus seasonal or year-round monoclonal antibody program in Norwegian children. J. Infect. Dis. 226, S95\u2013s101 (2022).","journal-title":"J. Infect. Dis."},{"key":"1372_CR28","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.vaccine.2023.01.058","volume":"41","author":"AM Getaneh","year":"2023","unstructured":"Getaneh, A. M. et al. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries. Vaccine 41, 1623\u20131631 (2023).","journal-title":"Vaccine"},{"key":"1372_CR29","volume":"38","author":"D Hodgson","year":"2024","unstructured":"Hodgson, D. et al. Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination. Lancet Reg. Health Eur. 38, 100829 (2024).","journal-title":"Lancet Reg. Health Eur."},{"key":"1372_CR30","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jval.2022.11.014","volume":"26","author":"X Li","year":"2023","unstructured":"Li, X. et al. Cost-effectiveness of respiratory syncytial virus preventive interventions in children: a model comparison study. Value Health 26, 508\u2013518 (2023).","journal-title":"Value Health"},{"key":"1372_CR31","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13268","volume":"18","author":"E Uusitupa","year":"2024","unstructured":"Uusitupa, E., Waris, M., Vuorinen, T. & Heikkinen, T. Respiratory syncytial virus-associated hospitalizations in children: a 10-year population-based analysis in Finland, 2008-2018. Influenza Other Respir. Viruses 18, e13268 (2024).","journal-title":"Influenza Other Respir. Viruses"},{"key":"1372_CR32","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/bmj.p1021","volume":"381","author":"H Boytchev","year":"2023","unstructured":"Boytchev, H. Maternal RSV vaccine: further analysis is urged on preterm births. BMJ 381, 1021 (2023).","journal-title":"BMJ"},{"key":"1372_CR33","doi-asserted-by":"crossref","first-page":"e1004250","DOI":"10.1371\/journal.pmed.1004250","volume":"20","author":"M Antill\u00f3n","year":"2023","unstructured":"Antill\u00f3n, M. et al. The age profile of respiratory syncytial virus burden in preschool children of low- and middle-income countries: a semi-parametric, meta-regression approach. PLoS Med.20, e1004250 (2023).","journal-title":"PLoS Med"},{"key":"1372_CR34","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-024-09400-2","volume":"24","author":"F Giannini","year":"2024","unstructured":"Giannini, F., Hogan, A. B., Sarna, M., Glass, K. & Moore, H. C. Modelling respiratory syncytial virus age-specific risk of hospitalisation in term and preterm infants. BMC Infect. Dis. 24, 510 (2024).","journal-title":"BMC Infect. Dis."},{"key":"1372_CR35","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.vaccine.2018.03.006","volume":"36","author":"C Chen","year":"2018","unstructured":"Chen, C., Beutels, P. & Newall, A. T. Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination. Vaccine 36, 2057\u20132060 (2018).","journal-title":"Vaccine"},{"key":"1372_CR36","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1016\/j.vaccine.2018.08.084","volume":"36","author":"C Chen","year":"2018","unstructured":"Chen, C. et al. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. Vaccine 36, 6307\u20136313 (2018).","journal-title":"Vaccine"},{"key":"1372_CR37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.vaccine.2015.11.053","volume":"34","author":"AT Newall","year":"2016","unstructured":"Newall, A. T. et al. Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical. Vaccine 34, 320\u2013327 (2016).","journal-title":"Vaccine"},{"key":"1372_CR38","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.vaccine.2013.11.067","volume":"32","author":"AT Newall","year":"2014","unstructured":"Newall, A. T. et al. Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. Vaccine 32, 759\u2013765 (2014).","journal-title":"Vaccine"},{"key":"1372_CR39","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.vaccine.2016.11.056","volume":"35","author":"JF Reyes","year":"2017","unstructured":"Reyes, J. F. et al. Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia. Vaccine 35, 345\u2013352 (2017).","journal-title":"Vaccine"},{"key":"1372_CR40","volume":"18","author":"X Li","year":"2020","unstructured":"Li, X. et al. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. BMC Med. 18, 82 (2020).","journal-title":"BMC Med."},{"key":"1372_CR41","unstructured":"World Health Organization. WHO Guide for Standardization of Economic Evaluations of Immunization Programmes (World Health Organization, 2019)."},{"key":"1372_CR42","doi-asserted-by":"crossref","unstructured":"Neyt, M., Thiry, N. & Cleemput, I. Belgian Guidelines for Economic Evaluations and Budget Impact Analyses 3rd edn (Belgian Health Care Knowledge Centre (KCE), 2025).","DOI":"10.57598\/R400C"},{"key":"1372_CR43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1017\/S0266462314000725","volume":"30","author":"N Thiry","year":"2014","unstructured":"Thiry, N., Neyt, M., Van De Sande, S. & Cleemput, I. Belgian guidelines for economic evaluations: second edition. Int. J. Technol. Assess. Health Care 30, 601\u2013607 (2014).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"1372_CR44","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/0272989X211045070","volume":"42","author":"J Bilcke","year":"2022","unstructured":"Bilcke, J. & Beutels, P. Generating, presenting, and interpreting cost-effectiveness results in the context of uncertainty: a tutorial for deeper knowledge and better practice. Med. Decis. Mak. 42, 421\u2013435 (2022).","journal-title":"Med. Decis. Mak."},{"key":"1372_CR45","unstructured":"UK Health Security Agency. RSV Maternal Vaccination Coverage in England: September 2024, <https:\/\/www.gov.uk\/government\/publications\/rsv-immunisation-for-older-adults-and-pregnant-women-vaccine-coverage-in-england\/rsv-maternal-vaccination-coverage-in-england-september-2024> (2025)."},{"key":"1372_CR46","unstructured":"Sciensano. Primary Risk Assessment: Increase in Cases of Pertussis, <https:\/\/www.sciensano.be\/sites\/default\/files\/20231002_rag_pra_pertussis.pdf> (2023)."},{"key":"1372_CR47","unstructured":"Superior Health Council. Maternal Immunisation: Belgian Guidelines, <https:\/\/www.health.belgium.be\/sites\/default\/files\/uploads\/fields\/fpshealth_theme_file\/20201106_shc-8754_maternal_immunisation_vweb.pdf> (2020)."},{"key":"1372_CR48","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1016\/j.vaccine.2018.03.033","volume":"36","author":"K Maertens","year":"2018","unstructured":"Maertens, K. et al. Coverage of recommended vaccines during pregnancy in Flanders, Belgium. Fairly good but can we do better? Vaccine 36, 2687\u20132693 (2018).","journal-title":"Vaccine"},{"key":"1372_CR49","unstructured":"Theeten, H., Braeckman, T., Maertens, K., Blaizot, S. & Van Damme, P. Studie van de vaccinatiegraad in Vlaanderen 2016 (Vaccinaties Vaccin en Infectieziekten Instituut, Universiteit Antwerpen 2017)."},{"key":"1372_CR50","unstructured":"Maertens, K. et al. Studie van de vaccinatiegraad in Vlaanderen. (2022)."},{"key":"1372_CR51","unstructured":"World Health Organization & UNICEF. WHO\/UNICEF Estimates of National Immunization Coverage, <https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/immunization-analysis-and-insights\/global-monitoring\/immunization-coverage\/who-unicef-estimates-of-national-immunization-coverage> (2025)."},{"key":"1372_CR52","unstructured":"Robert, E., Swennen, B. & Coppieters, Y. Enqu\u00eate de couverture vaccinale des enfants de 18 \u00e0 24 mois Bruxelles-Capital (ULB\u2014\u00c9cole de Sant\u00e9 Publique, 2020)."},{"key":"1372_CR53","unstructured":"Grammens, T. & Cornelissen, L. Couverture vaccinale des vaccinations de base (Sciensano.be, 2021)."},{"key":"1372_CR54","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2365804","volume":"20","author":"JJ Perez Martin","year":"2024","unstructured":"Perez Martin, J. J. & Zornoza Moreno, M. Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain. Hum. Vaccin Immunother. 20, 2365804 (2024).","journal-title":"Hum. Vaccin Immunother."},{"key":"1372_CR55","doi-asserted-by":"publisher","unstructured":"Morris, T. et al. Lessons from implementing a long-acting monoclonal antibody (nirsevimab) for RSV in France, Spain and the US. Discov. Health Syst. 4. https:\/\/doi.org\/10.1007\/s44250-025-00198-7 (2025).","DOI":"10.1007\/s44250-025-00198-7"},{"key":"1372_CR56","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/infdis\/jiad188","volume":"228","author":"M Del Riccio","year":"2023","unstructured":"Del Riccio, M. et al. Burden of respiratory syncytial virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years. J. Infect. Dis. 228, 1528\u20131538 (2023).","journal-title":"J. Infect. Dis."},{"key":"1372_CR57","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00431-022-04698-z","volume":"182","author":"M Raes","year":"2023","unstructured":"Raes, M. et al. The burden and surveillance of RSV disease in young children in Belgium-expert opinion. Eur. J. Pediatr. 182, 451\u2013460 (2023).","journal-title":"Eur. J. Pediatr."},{"key":"1372_CR58","unstructured":"STATBEL. Births Annual by District 2008-2023, <https:\/\/statbel.fgov.be\/en\/themes\/population\/population-movement\/births#figures> (2025)."},{"key":"1372_CR59","unstructured":"STATBEL. Life Tables, Yearly, in Exact Age, <https:\/\/statbel.fgov.be\/en\/themes\/population\/mortality-life-expectancy-and-causes-death\/life-expectancy-and-life-tables#figures> (2025)."},{"key":"1372_CR60","unstructured":"BELSARI-NET. BELSARI-NET Research Group <https:\/\/www.sciensano.be\/fr\/file\/belsari-net-research-group> (2025)."},{"key":"1372_CR61","doi-asserted-by":"crossref","first-page":"e13344","DOI":"10.1111\/irv.13344","volume":"18","author":"S Heemskerk","year":"2024","unstructured":"Heemskerk, S. et al. Disease burden of RSV infections and bronchiolitis in young children (< 5 Years) in primary care and emergency departments: a systematic literature review. Influenza Other Respir. Viruses 18, e13344 (2024).","journal-title":"Influenza Other Respir. Viruses"},{"key":"1372_CR62","doi-asserted-by":"publisher","unstructured":"Hak, S. F. et al. Burden of RSV infections among young children in primary care: a prospective cohort study in five European countries (2021-23). Lancet Respir. Med. https:\/\/doi.org\/10.1016\/S2213-2600(24)00367-9 (2025).","DOI":"10.1016\/S2213-2600(24)00367-9"},{"key":"1372_CR63","doi-asserted-by":"publisher","unstructured":"Sankatsing, V. D. et al. Economic impact of RSV infections in young children attending primary care: a prospective cohort study in five European countries, 2021 to 2023. Euro Surveill 30. https:\/\/doi.org\/10.2807\/1560-7917.ES.2025.30.20.2400797 (2025).","DOI":"10.2807\/1560-7917.ES.2025.30.20.2400797"},{"key":"1372_CR64","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40261-021-01057-y","volume":"41","author":"X Li","year":"2021","unstructured":"Li, X. et al. Direct and indirect costs of influenza-like illness treated with and without oseltamivir in 15 European countries: a descriptive analysis alongside the randomised controlled ALIC(4)E trial. Clin. Drug Investig. 41, 685\u2013699 (2021).","journal-title":"Clin. Drug Investig."},{"key":"1372_CR65","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1093\/infdis\/jiad477","volume":"229","author":"SF Hak","year":"2024","unstructured":"Hak, S. F. et al. Substantial burden of nonmedically attended RSV infection in healthy-term infants: an international prospective birth cohort study. J. Infect. Dis. 229, S40\u2013S50 (2024).","journal-title":"J. Infect. Dis."},{"key":"1372_CR66","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s10198-022-01521-2","volume":"24","author":"X Li","year":"2023","unstructured":"Li, X. et al. Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC(4)E trial in 15 European countries. Eur. J. Health Econ. 24, 909\u2013922 (2023).","journal-title":"Eur. J. Health Econ."},{"key":"1372_CR67","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11136-021-02971-6","volume":"31","author":"L Van Wilder","year":"2022","unstructured":"Van Wilder, L. et al. Belgian population norms for the EQ-5D-5L, 2018. Qual. Life Res. 31, 527\u2013537 (2022).","journal-title":"Qual. Life Res."},{"key":"1372_CR68","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt, L. L. et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N. Engl. J. Med. 386, 837\u2013846 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1372_CR69","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMc2214773","volume":"388","author":"WJ Muller","year":"2023","unstructured":"Muller, W. J. et al. Nirsevimab for prevention of RSV in term and late-preterm infants. N. Engl. J. Med 388, 1533\u20131534 (2023).","journal-title":"N. Engl. J. Med"},{"key":"1372_CR70","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","volume":"7","author":"EAF Simoes","year":"2023","unstructured":"Simoes, E. A. F. et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc. Health 7, 180\u2013189 (2023).","journal-title":"Lancet Child Adolesc. Health"},{"key":"1372_CR71","doi-asserted-by":"crossref","unstructured":"Briggs, A. C., K. Sculpher, M. Decision Modelling for Health Economic Evaluation (Oxford University Press, 2006).","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"1372_CR72","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/0272989X07312474","volume":"28","author":"S Eckermann","year":"2008","unstructured":"Eckermann, S., Briggs, A. & Willan, A. R. Health technology assessment in the cost-disutility plane. Med. Decis. Mak. 28, 172\u2013181 (2008).","journal-title":"Med. Decis. Mak."},{"key":"1372_CR73","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jval.2019.02.008","volume":"22","author":"F Alarid-Escudero","year":"2019","unstructured":"Alarid-Escudero, F., Enns, E. A., Kuntz, K. M., Michaud, T. L. & Jalal, H. Time traveling is just too dangerous but some methods are worth revisiting: the advantages of expected loss curves over cost-effectiveness acceptability curves and frontier. Value Health 22, 611\u2013618 (2019).","journal-title":"Value Health"},{"key":"1372_CR74","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/0272989X20937253","volume":"40","author":"Z Pieters","year":"2020","unstructured":"Pieters, Z., Strong, M., Pitzer, V. E., Beutels, P. & Bilcke, J. A computationally efficient method for probabilistic parameter threshold analysis for health economic evaluations. Med. Decis. Mak. 40, 669\u2013679 (2020).","journal-title":"Med. Decis. Mak."},{"key":"1372_CR75","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s11136-017-1556-y","volume":"26","author":"J Bilcke","year":"2017","unstructured":"Bilcke, J., Hens, N. & Beutels, P. Quality-of-life: a many-splendored thing? Belgian population norms and 34 potential determinants explored by beta regression. Qual. Life Res. 26, 2011\u20132023 (2017).","journal-title":"Qual. Life Res."},{"key":"1372_CR76","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/apa.12863","volume":"104","author":"S Bergfors","year":"2015","unstructured":"Bergfors, S., Astrom, M., Burstrom, K. & Egmar, A. C. Measuring health-related quality of life with the EQ-5D-Y instrument in children and adolescents with asthma. Acta Paediatr. 104, 167\u2013173 (2015).","journal-title":"Acta Paediatr."},{"key":"1372_CR77","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12955-022-01955-5","volume":"20","author":"K Mayoral","year":"2022","unstructured":"Mayoral, K. et al. Measurement properties of the EQ-5D-Y administered through a smartphone app in children with asthma: a longitudinal questionnaire study. Health Qual. Life Outcomes 20, 51 (2022).","journal-title":"Health Qual. Life Outcomes"},{"key":"1372_CR78","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1017\/S0266462309990171","volume":"25","author":"DC Willems","year":"2009","unstructured":"Willems, D. C. et al. Using EQ-5D in children with asthma, rheumatic disorders, diabetes, and speech\/language and\/or hearing disorders. Int. J. Technol. Assess. Health Care 25, 391\u2013399 (2009).","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"1372_CR79","unstructured":"STATBEL. An Overview of Belgian Wages and Salaries, <https:\/\/statbel.fgov.be\/en\/themes\/work-training\/wages-and-labourcost\/overview-belgian-wages-and-salaries#news> (2024)."},{"key":"1372_CR80","doi-asserted-by":"publisher","unstructured":"Kampmann, B. et al. Bivalent prefusion f vaccine in pregnancy to prevent RSV illness in infants. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2216480 (2023).","DOI":"10.1056\/NEJMoa2216480"},{"key":"1372_CR81","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103281","volume":"84","author":"D Trusinska","year":"2025","unstructured":"Trusinska, D. et al. Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis. EClinicalMedicine 84, 103281 (2025).","journal-title":"EClinicalMedicine"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01372-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01372-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01372-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:16:24Z","timestamp":1771427784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01372-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1372"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01372-5","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Outside the submitted work, P.B. declares no competing non-financial Interests but the following competing financial Interests: funding received by his institute from Merck for research on varicella-zoster and Pfizer for research on pneumococcal vaccine, but he has not received any personal fees or other personal benefits. XL declares no competing non-financial Interests but the following competing financial Interests: funding received by her institute from Icosavax, and from GSK for an educational symposium, as well as consultancy fees received from IQVIA Belgium, all unrelated to the submitted work. Other authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}